Financial Performance - The company recorded a net income of approximately $8.6 million for the year ended December 31, 2024, compared to a net loss of $4.9 million for 2023, with an accumulated deficit of approximately $181.9 million as of December 31, 2024[85]. - Total assets increased to $68,278 million in 2024 from $54,964 million in 2023, representing a growth of 24.1%[266]. - Net sales for 2024 reached $99,597 million, up 19.2% from $83,570 million in 2023[268]. - Gross profit improved to $61,586 million in 2024, a 21.4% increase compared to $50,780 million in 2023[268]. - Operating income turned positive at $7,726 million in 2024, compared to an operating loss of $5,599 million in 2023[268]. - Cash and cash equivalents increased to $44,660 million at the end of 2024, up from $27,325 million at the end of 2023, marking a 63.7% increase[273]. - Total stockholders' equity rose to $46,094 million in 2024 from $28,456 million in 2023, reflecting a growth of 62.0%[266]. - The company anticipates that its current cash and cash equivalents, along with cash generated from net sales, will be sufficient to meet financial obligations for at least the next twelve months[314]. Competition and Market Risks - The company faces significant competition from larger companies with greater financial resources, which may impact its market position and ability to launch new products[94]. - The company faces intense competition in its markets, with competitors potentially developing superior technologies that could harm its business[98]. - Economic conditions, including inflation and geopolitical issues, may negatively impact the company's business, financial condition, and share price, leading to decreased demand for its products[88]. - The success of the company's consumer product business is linked to the growth rate of the wellness industry market, particularly the dietary supplement market[91]. Operational Challenges - The company relies on a single supplier for key raw materials, which poses risks to its production capabilities and overall business operations[84]. - The company relies on contract manufacturers for pharmaceutical-grade Niagen®, and any failure by these facilities could significantly impact the ability to meet consumer demand[124]. - The company may struggle to monetize its products for pharmaceutical applications due to challenges in securing partnerships and regulatory approvals[114]. - The company may need to restructure its operations in response to changing market conditions, which could increase costs and impact profitability[97]. - The company relies on key personnel for its operations, and the loss of any critical team members could adversely affect its business[113]. Regulatory and Compliance Risks - Regulatory approvals for the company's products may be difficult to obtain or maintain, potentially leading to narrower approved indications than desired[136]. - The company faces significant compliance costs and potential liabilities related to evolving data privacy and security regulations[154]. - Changes in government regulations could impact the demand for the company's products and services, as well as its ability to comply with new regulations[146]. - The company must navigate complex data transfer regulations following the UK's withdrawal from the EEA, increasing its compliance burden[150]. Research and Development - Research and development expenses increased to $6,016 million in 2024, up 21.4% from $4,958 million in 2023, indicating a focus on innovation[268]. - The company has invested substantial resources in developing new products, but commercialization may require additional investment and regulatory approval[133]. Financial Position and Capital Needs - The company may require additional financing to meet long-term capital requirements, with potential funding sources including equity or debt financings, but there are no commitments for such financing[86]. - The company may seek additional capital within the next twelve months to fund projected operating plans and longer-term strategic objectives[314]. - The company has never paid cash dividends and does not anticipate doing so in the foreseeable future, limiting returns on investment to stock price appreciation[164]. Customer and Vendor Concentration - Major customers accounted for 12.5% and 11.7% of revenues in 2024 from A.S. Watson Group and Life Extension, respectively[323]. - As of December 31, 2024, approximately 72% of the total outstanding trade receivables were concentrated among three customers, posing a potential risk to financial performance[329]. - The Company has a major vendor, Vendor A, accounting for 47.2% of total accounts payable as of December 31, 2024, down from 64.3% in 2023[331]. Stock and Equity - The company has approximately 10.4 million outstanding options at a weighted average exercise price of $3.27 per share, which could affect the market price of its common stock[165]. - The company may experience significant dilution of stockholder equity if future operations or acquisitions are financed through additional equity offerings[179]. - The company’s stock may be thinly traded, leading to challenges in selling shares at desired prices[178]. Environmental, Social, and Governance (ESG) Considerations - The company faces increased scrutiny regarding its environmental, social, and governance (ESG) practices, which may lead to additional costs and risks[172]. - New California laws, effective in 2026, will impose broad climate-related disclosure obligations on certain companies, potentially affecting operations and increasing expenses[172]. - Investor advocacy groups are increasingly focused on ESG practices, which may influence investment decisions away from the company if perceived inadequacies exist[174].

Company Performance - ChromaDex shares have increased by 122.5% over the past month, reaching a 52-week high of $7.85 [1] - The stock has gained 433.6% since the beginning of the year, contrasting with a -0.2% change in the Zacks Medical sector and a -8.2% return in the Zacks Medical - Biomedical and Genetics industry [1] Earnings and Revenue - ChromaDex has consistently exceeded earnings expectations, reporting EPS of $0.02 against a consensus estimate of $0.01 in its last earnings report on October 31, 2024, and beating revenue estimates by 7.93% [2] - For the current fiscal year, ChromaDex is projected to achieve earnings of $0.04 per share on revenues of $97.55 million, reflecting a 157.14% increase in EPS and a 16.73% increase in revenues [3] - The next fiscal year forecasts earnings of $0.12 per share on $120.8 million in revenues, indicating a year-over-year change of 200% in EPS and 23.83% in revenues [3] Valuation Metrics - ChromaDex has a Value Score of D, with Growth and Momentum Scores of A and C, respectively, resulting in a VGM Score of B [6] - The stock trades at 190.8X current fiscal year EPS estimates, significantly higher than the peer industry average of 22.8X, while on a trailing cash flow basis, it trades at 5X compared to the peer group's average of 14.6X [6] Zacks Rank - ChromaDex holds a Zacks Rank of 2 (Buy), supported by favorable earnings estimate revisions from analysts [7] - The stock meets the criteria for selection, as it has a Zacks Rank of 1 (Strong Buy) or 2 (Buy) and Style Scores of A or B, suggesting potential for further gains [7] Industry Comparison - In comparison to industry peers, Jazz Pharmaceuticals PLC (JAZZ) also shows strong performance with a Zacks Rank of 2 (Buy) and favorable Value, Growth, and Momentum Scores [8] - JAZZ has reported earnings exceeding consensus estimates by 20.84% and is expected to post earnings of $22.16 per share on revenues of $4.04 billion for the current fiscal year [9] - The Medical - Biomedical and Genetics industry is performing well, ranking in the top 25% of all industries, providing a positive backdrop for both ChromaDex and JAZZ [10]

Core Viewpoint - The article emphasizes the importance of identifying and sustaining trends in short-term investing, highlighting that sound fundamentals and positive earnings estimates are crucial for maintaining momentum in stock prices [1]. Group 1: Stock Performance - ChromaDex (CDXC) has shown a significant price increase of 122.6% over the past 12 weeks, indicating strong investor interest and potential upside [3]. - The stock has also experienced a price increase of 116.8% over the last four weeks, suggesting that the upward trend is still intact [4]. - CDXC is currently trading at 97.3% of its 52-week high-low range, indicating a potential breakout opportunity [4]. Group 2: Fundamental Strength - CDXC holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, which are key indicators of near-term price movements [5]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term performance [6]. Group 3: Investment Strategy - The article suggests that investors can utilize the "Recent Price Strength" screen to identify stocks like CDXC that are on an upward trend supported by strong fundamentals [2]. - There are over 45 Zacks Premium Screens available for investors to choose from, tailored to different investing styles and aimed at outperforming the market [7].

Core Insights - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] - ChromaDex (CDXC) currently holds a Momentum Style Score of A, indicating strong momentum characteristics [2] - The Zacks Rank for ChromaDex is 2 (Buy), suggesting a favorable outlook for the stock based on historical performance metrics [3] Performance Metrics - ChromaDex shares have increased by 68.88% over the past week, while the Zacks Medical - Biomedical and Genetics industry has declined by 0.75% during the same period [5] - Over the last quarter, CDXC shares have risen by 105.46%, and over the past year, they have gained 376.76%, significantly outperforming the S&P 500, which increased by 15.2% and 38.09% respectively [6] - The average 20-day trading volume for CDXC is 2,538,904 shares, indicating strong trading activity [7] Earnings Outlook - In the past two months, three earnings estimates for ChromaDex have been revised upwards, while none have been lowered, leading to an increase in the consensus estimate from $0.01 to $0.04 [9] - For the next fiscal year, two estimates have moved up, while one has been revised down [9] - Overall, ChromaDex is positioned as a 2 (Buy) stock with a Momentum Score of A, making it a potential candidate for near-term investment [9]

Company Performance - ChromaDex (CDXC) shares have increased by 72.9% over the past month, reaching a new 52-week high of $6.18 [1] - Since the beginning of the year, ChromaDex has gained 301.4%, significantly outperforming the Zacks Medical sector's 3.1% increase and the -2.3% return of the Zacks Medical - Biomedical and Genetics industry [1] Earnings and Valuation - ChromaDex has consistently exceeded earnings expectations, reporting an EPS of $0.02 against a consensus estimate of $0.01 in its latest earnings report on October 31, 2024, and beating revenue estimates by 7.93% [2] - The stock currently trades at a valuation of 246X current fiscal year EPS estimates, which is a premium compared to the peer industry average of 24.1X [5] Zacks Rank and Style Scores - ChromaDex holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, indicating strong potential for further gains [6] - The company has a Value Score of D, while its Growth and Momentum Scores are both A, resulting in a combined VGM Score of B [5][6] Industry Comparison - MiMedx Group, Inc (MDXG) is a notable competitor, holding a Zacks Rank of 2 (Buy) with strong earnings performance, having beaten consensus estimates by 40% last quarter [7][8] - The Medical - Biomedical and Genetics industry is positioned in the top 38% of all industries, suggesting favorable conditions for both ChromaDex and MiMedx Group [9]

Core Viewpoint - The article emphasizes the importance of identifying sustainable trends in short-term investing, highlighting that while price momentum can be profitable, it requires strong fundamentals to maintain that momentum [1][2]. Group 1: Stock Performance - ChromaDex (CDXC) has shown a significant price increase of 103.9% over the past 12 weeks, indicating strong investor interest [4]. - The stock has also increased by 72.9% in the last four weeks, suggesting that the upward trend is still intact [5]. - CDXC is currently trading at 91% of its 52-week high-low range, indicating a potential breakout [5]. Group 2: Fundamental Strength - CDXC holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises [6]. - The stock has an Average Broker Recommendation of 1 (Strong Buy), reflecting high optimism from the brokerage community regarding its near-term price performance [7]. - Historically, Zacks Rank 1 stocks have generated an average annual return of +25% since 1988, showcasing the effectiveness of this ranking system [7]. Group 3: Investment Strategy - The "Recent Price Strength" screen is a useful tool for identifying stocks with strong fundamentals that can maintain their upward momentum [3]. - In addition to CDXC, there are other stocks that meet the criteria of the "Recent Price Strength" screen, suggesting further investment opportunities [8]. - The Zacks Research Wizard allows investors to backtest stock-picking strategies, enhancing the likelihood of selecting profitable stocks [9].

| --- | |-------| | | | | | | | | | | | | | | | | | | Rob Fried Chief Executive Officer Ozan Pamir Chief Financial Officer Andrew Shao SVP Scientific & Regulatory Affairs Nasdaq: CDXC | October 31, 2024 SAFE HARBOR STATEMENT 2 This presentation and other written or oral statements made from time to time by representatives of ChromaDex contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as am ...

ChromaDex (CDXC) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to loss of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 100%. A quarter ago, it was expected that this natural products company would post a loss of $0.03 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the compa ...

ChromaDex Corporation Reports Third Quarter 2024 Financial Results Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and Adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024. LOS ANGELES, CA - October 31, 2024 - ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024. Third Quarter 2024 Financial and Recent Operational Highlights • Total net sales ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Commission File Number: 001-37752 CHROMADEX CORPORATION (Exact Name of Registrant as Specified in its Charter) | --- | --- | --- | |----------------------------------------------------------------------------------|----------------------------|---------------------------------------------- ...